Description:
This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and
Pharmacokinetics of NB004 in Subjects with Advanced Solid Tumors
Title
- Brief Title: A Study of NB003 in Patients With Advanced Malignancies
- Official Title: A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Malignancies
Clinical Trial IDs
- ORG STUDY ID:
NB003-01
- NCT ID:
NCT04936178
Conditions
Interventions
Drug | Synonyms | Arms |
---|
NB003 tablets | | NB003 |
Purpose
This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and
Pharmacokinetics of NB004 in Subjects with Advanced Solid Tumors
Detailed Description
This is a phase 1, open-label, multicenter study of NB003 administered orally in patients
with advanced GIST who have progressed on or had an intolerability to imatinib and other
standard of care (SoCs) or refused other SoCs, and patients with an advanced malignancy other
than Gastrointestinal stromal tumor (GIST)that harbors KIT(CD117) or platelet derived growth
factor receptor(PDGFRa) gene alteration who have relapsed or have refractory disease without
an available effective therapy.
The study is comprised of a dose escalation phase to determine the MTD and the RP2D and an
expansion phase to further explore the safety and efficacy of NB003.
Trial Arms
Name | Type | Description | Interventions |
---|
NB003 | Experimental | Dose escalation cohort: NB003 tablets will be administered orally twice daily for repeated 28-day cycles until discontinuation criteria are met. | |
Eligibility Criteria
Inclusion Criteria:
1. Males or females of any race ≥18 years age.
2. Histologically-confirmed diagnosis of unresectable, relapsed or metastatic GIST or
another advanced solid tumor. GIST patients must have progressed on or had an
intolerability to imatinib and other SoCs or refused other SoCs. Patients with an
advanced solid tumor other than GIST must have relapsed or had refractory disease
without an available effective therapy and harbor KIT or PDGFRa gene alteration.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. Life expectancy ≥ 12 weeks.
5. Adequate organ and marrow function.
6. Tumor sample collection is required.
Exclusion Criteria:
1. Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is
longer, before the first dose.
2. Major surgery within 4 weeks of the first dose.
3. Radiotherapy with a limited field of radiation for palliation within 1 week prior to
the first dose, with the exception as defined.
4. Patients currently receiving medications or herbal supplements known to be strong
inhibitors or inducers of CYP3A4.
5. Patients currently receiving acid-reducing agents and are unable to stop use at least
2 weeks prior to the first dose.
6. Spinal cord compression or brain metastases.
7. Active infection including hepatitis B, hepatitis C, and HIV.
8. Any evidence of severe or uncontrolled systemic diseases which in the Investigator's
opinion makes it undesirable for the patient to participate in the trial or which
would jeopardize compliance with the protocol.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Incidence of dose-limiting toxicities |
Time Frame: | Approximately 24 months since the first subject enrolled |
Safety Issue: | |
Description: | Dose-limiting toxicities will be reviewed as a subset of adverse events that occur within the first 28 days of dosing and meet protocol-specified criteria. |
Secondary Outcome Measures
Measure: | Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t) |
Time Frame: | Approximately 24 months since the first subject enrolled |
Safety Issue: | |
Description: | AUC (0-t) = Area under the serum concentration versus time curve from time zero (pre-dose) to the time of the last measurable concentration. |
Measure: | Maximum observed plasma concentration (Cmax) |
Time Frame: | Approximately 24 months since the first subject enrolled |
Safety Issue: | |
Description: | Maximum observed plasma concentration (Cmax) |
Measure: | Time to Cmax (Tmax) |
Time Frame: | Approximately 24 months since the first subject enrolled |
Safety Issue: | |
Description: | Time to Cmax (Tmax) |
Measure: | Terminal elimination half life |
Time Frame: | Approximately 24 months since the first subject enrolled |
Safety Issue: | |
Description: | Terminal elimination half life |
Measure: | Objective Response Rate (ORR) |
Time Frame: | Approximately 24 months since the first subject enrolled |
Safety Issue: | |
Description: | Objective Response Rate (ORR) which is defined as the percentage of patients whose efficacy is confirmed as complete response(CR) or partial responses(PR) |
Measure: | Duration of Response(DOR) |
Time Frame: | Approximately 24 months since the first subject enrolled |
Safety Issue: | |
Description: | DOR is defined as the time from the date of first documented response until date of documented progression, for subjects who achieve CR or PR. |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Ningbo Newbay Technology Development Co., Ltd |
Last Updated
August 10, 2021